ScholarIQanswers from OpenAlex

Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients

PaperCitations, authors & open-access status

Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients have?

ScholarIQcitation count

Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients has 136 citations in the OpenAlex counts ScholarIQ stores.

When was Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients published?

ScholarIQyear

Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients has 2018 year in the ScholarIQ index.

What is the open-access status of Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients?

ScholarIQoa status

Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients has green oa status in the ScholarIQ index.

What is the DOI of Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients?

ScholarIQdoi

The DOI for Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients is on the source record.

What is the PMID of Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients?

ScholarIQpmid

The PMID for Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients is on the source record.

What is the OpenAlex record for Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients?

ScholarIQopenalex

The OpenAlex for Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial